THE STUDY OF THE VASOPROSTAN, LOSARTAN AND ANTIOXIDATIVE FORMULATION EFFECTS ON THE COURSE OF ACUTE KIDNEY INJURY IN RATS EXPOSED TO ETHYLENE GLYCOL

THE AIM OF THE STUDY was to investigate the effects of drugs with endothelio- and renoprotective activity on the course of acute kidney injury (AKI) in rats after the severe ethylene glycol poisoning. MATERIALS AND METHODS. AKI was examined on rat model by intragastric administration of 2/3 LD50 ethylene glycol. After poisoning rats were divided into groups and treated daily with losartan, vasoprostan and antioxidative formulation (AF) for 7 days. The control group was treated with saline solution. Diurnal dieresis rates, serum creatinine and urea concentrations were analyzed at 3, 7, 14 and 28 days following poisoning. Urinary sediment was also assessed. The received data were compared with intact animals. RESULTS. It was noticed the decrease in lethality in group treated with vasoprostan and AF and 4-fold increase in this rate after losartan treatment. Among all the drugs tested only vasoprostan significantly decreased azotemia level 2 days after exposure to the toxicant. On the contrary, losartan administration leaded to more than 8- and 18-fold increase of creatinine and urea, respectively. Vasoprostan and AF improved the reparation of renal functions from 14 (untreated group) to 7 (treated group) days. Daily urine production in these groups was 1.5- and 4-fold greater than in control and intact rats. Among all the drugs tested only AF administration in 14-28 days after ethylene glycol poisoning resulted in restoration of normal daily urine production. CONCLUSION. Administration of losartan in ethylene glycol poisoning is associated with risk of ARF transition to the decompensation stage. Vasoprostan and AF administration improve restoration of ethylene glycol-induced AKI.

1. Adhiyaman V. Nephrotoxicity in the elderly due to coprescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med 2001; 94 (10): 512-514

2. De Broe ME. Clinical nephrotoxins. Renal injury from drugs and chemicals, Second Edition. Springer Science 2004; 712

3. Tarloff JB, Lash LH. Тoxicology of the Kidney, 3-rd Edition (Target Organ Toxicology Series). Inform HealthCare 2004; 1200

4. Пермяков АВ, Витер ВИ, Неволин НИ. Судебномедицинская гистология Руководство для врачей. (Изд. второе, перераб. и доп.). Экспертиза, Ижевск-Екатеринбург, 2003; 214

5. Sun D, Liu CX, Ma YY, Zhang L. Protective effect of prostaglandin E1 on renal microvascular injury in rats of acute aristolochic acid nephropathy. Ren Fail 2011; 33 (2): 225-232

6. Li JS, Sharifi AM, Schiffrin EL. Effect of AT1 angiotensinreceptor blockade on structure and function of small arteries in SHR. J Cardiovasc Pharmacol 1997; 30 (1): 75-83

7. Фомичев АВ. Оценка нарушений умственной и физической работоспособности при острых нетяжелых отравлениях нейротропными веществами и их фармакологическая коррекция антиоксидантами. Автореф. дисс. … канд. мед. наук, ВМедА, СПб, 2004; 38

8. Caravati EM, Erdman AR, Christianson G et al. Ethylene glycol exposure: an evidence-based consensus guideline for outof-hospital management. Clin Toxicol 2005; 43: 327–345

9. Хабриев РУ. Руководство по экспериментальному (доклиничесому) изучению новых фармакологических веществ. «Медицина», М., 2005; 102